Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Retained Earnings (2019 - 2026)

Pliant Therapeutics has reported Retained Earnings over the past 8 years, most recently at -$341000.0 for Q1 2026.

  • Quarterly Retained Earnings rose 99.96% to -$341000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$341000.0 through Mar 2026, up 99.96% year-over-year, with the annual reading at -$859.4 million for FY2025, 21.03% down from the prior year.
  • Retained Earnings was -$341000.0 for Q1 2026 at Pliant Therapeutics, up from -$859.4 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $848000.0 in Q3 2024 and troughed at -$859.4 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$2.0 million (2022), against an average of -$249.4 million.
  • Year-over-year, Retained Earnings soared 144.47% in 2024 and then crashed 156590.8% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$2.0 million in 2022, then tumbled by 25423.39% to -$499.7 million in 2023, then crashed by 42.08% to -$710.1 million in 2024, then fell by 21.03% to -$859.4 million in 2025, then surged by 99.96% to -$341000.0 in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Retained Earnings are -$341000.0 (Q1 2026), -$859.4 million (Q4 2025), and $34000.0 (Q3 2025).